SCHEMBL2148493

SCHEMBL2148493

CC(=O)Oc1c(C(=O)O)cc(O)c2c1C(=O)c1cccc(O)c1C2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.51
MAPT P10636 5/20 0.51
KDM4E B2RXH2 5/20 0.51
TTR P02766 4/20 0.51
HPGD P15428 4/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
FTO Q9C0B1 3/20 0.51
RECQL P46063 3/20 0.51
TSHR P16473 3/20 0.51
TDP1 Q9NUW8 3/20 0.51
LMNA P02545 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
HSD17B10 Q99714 3/20 0.51
POLB P06746 2/20 0.51
CYP3A4 P08684 2/20 0.51
ALOX15 P16050 2/20 0.51
HSP90AA1 P07900 2/20 0.51
HSP90AB1 P08238 2/20 0.51
CASP7 P55210 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8996444 0.90 TTR (0.47) ALDH1A1MAPTKDM4ETTRHPGD
SCHEMBL8996409 0.80 KDM4E (0.64) ALDH1A1MAPTKDM4ETTRHPGD
SCHEMBL8996324 0.80 FTO (0.68) ALDH1A1MAPTKDM4ETTRHPGD
SCHEMBL8963432 0.78 ALDH1A1 (0.57) ALDH1A1MAPTKDM4ETTRHPGD
SCHEMBL8996376 0.76 TTR (0.51) ALDH1A1MAPTKDM4ETTRHPGD
SCHEMBL22394347 0.74 PIM1 (0.63) ALDH1A1MAPTKDM4ETTRHPGD
SCHEMBL27916746 0.73 MAPT (0.57) ALDH1A1MAPTKDM4ETTRHPGD
SCHEMBL9538649 0.73 MEN1 (0.64) ALDH1A1MAPTKDM4ETTRHPGD
SCHEMBL11526641 0.73 PIM1 (0.69) ALDH1A1MAPTKDM4ETTRHPGD
SCHEMBL16459296 0.72 MAPT (0.45) ALDH1A1MAPTKDM4ETTRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116919957-A Methods and pharmaceutical compositions for preventing or treating immunoinflammatory skin disorders 安成生物科技股份有限公司 2023-10-24 CN disclosed
EP-3570835-B1 DIACEREIN FOR PREVENTING OR TREATING IMMUNOINFLAMMATORY DERMAL DISORDERS TWI BIOTECHNOLOGY INC (TW) 2023-08-09 EP disclosed
CN-110191710-B Method and pharmaceutical composition for preventing or treating immunoinflammatory skin disorders 安成生物科技股份有限公司 2023-04-18 CN disclosed
EP-4147694-A1 DIACEREIN OR ITS ANALOGS FOR INHIBITING EXPRESSION OF ASC, NLRP3, AND/OR FORMATION OF NLRP3 INFLAMMASOME COMPLEX TWI Biotechnology, Inc. (TW) 2023-03-15 EP disclosed
CN-108349867-B Diacerein or analogues thereof for inhibiting the expression of ASC, the expression of NLRP3 and/or the formation of NLRP3 inflammatory complex 安成生物科技股份有限公司 2021-03-09 CN disclosed
US-10675260-B2 Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders TWI BIOTECHNOLOGY, INC. (TW) 2020-06-09 US disclosed
US-20190105296-A1 DIACEREIN OR RHEIN TOPICAL FORMULATIONS AND USES THEREOF TWI BIOTECHNOLOGY, INC. (TW) 2019-04-11 US disclosed
EP-3452169-A1 METHODS AND FORMULATIONS FOR TREATMENT AND/OR PREVENTION OF BLOOD-ASSOCIATED DISORDERS TWI Biotechnology, Inc. (TW) 2019-03-13 EP disclosed
US-10195170-B2 Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs TWI BIOTECHNOLOGY, INC. (TW) 2019-02-05 US disclosed
US-10154984-B2 Diacerein or Rhein topical formulations and uses thereof TWI BIOTECHNOLOGY, INC. (TW) 2018-12-18 US disclosed
US-20110166225-A1 ORAL LIQUID COMPOSITIONS OF RHEIN OR DIACEREIN VERMA HIMANSHU 2011-07-07 US disclosed
US-20100303902-A1 SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN NAKHAT PREMCHAND 2010-12-02 US disclosed
US-20100285114-A1 PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN DABRE RAHUL 2010-11-11 US disclosed
EP-2224914-A2 RHEIN OR DIACEREIN COMPOSITIONS Wockhardt Research Centre (IN) 2010-09-08 EP disclosed
EP-2207531-A1 SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN Wockhardt Research Centre (IN) 2010-07-21 EP disclosed
EP-2207532-A2 PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN Wockhardt Research Centre (IN) 2010-07-21 EP disclosed
WO-2009040702-A2 PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN WOCKHARDT RESEARCH CENTRE (IN) 2009-04-02 WO disclosed
WO-2009040776-A1 SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN WOCKHARDT RESEARCH CENTRE (IN) 2009-04-02 WO disclosed
WO-2009034409-A2 PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN WOCKHARDT RESEARCH CENTRE (IN) 2009-03-19 WO disclosed
WO-2009034558-A2 RHEIN OR DIACEREIN COMPOSITIONS WOCKHARDT RESEARCH CENTRE (IN) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10154984-B2 Diacerein or Rhein topical formulations and uses thereof RFTN1, LRAT, RDX ALDH1A1 4155/4885MAPT 1042/4885KDM4E 4735/4885
US-10675260-B2 Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders TSLP, CUTA, MMP1 ALDH1A1 743/4885MAPT 1373/4885KDM4E 3673/4885
US-20110166225-A1 ORAL LIQUID COMPOSITIONS OF RHEIN OR DIACEREIN RCN1, RDX, RPN1 ALDH1A1 4424/4885MAPT 2616/4885KDM4E 4347/4885
US-10195170-B2 Methods for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex using diacerein or its analogs PYCARD, NLRP3, NOD1 ALDH1A1 3674/4885MAPT 1336/4885KDM4E 4530/4885
US-20100303902-A1 SELF-EMULSIFYING PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN SI, RDX, CETP ALDH1A1 3544/4885MAPT 3329/4885KDM4E 3517/4885
US-20100285114-A1 PHARMACEUTICAL COMPOSITIONS OF RHEIN OR DIACEREIN SI, HDAC10, RDX ALDH1A1 3719/4885MAPT 3622/4885KDM4E 3283/4885
US-20190105296-A1 DIACEREIN OR RHEIN TOPICAL FORMULATIONS AND USES THEREOF RFTN1, LRAT, RDX ALDH1A1 4155/4885MAPT 1042/4885KDM4E 4735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.